Literature DB >> 11126274

The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients.

S Fronhoffs1, J Luyken, K Steuer, M Hansis, H Vetter, P Walger.   

Abstract

OBJECTIVE: To evaluate the effect of adjunctive C1-esterase inhibitor substitution therapy on clinical characteristics and outcome of patients with streptococcal toxic shock syndrome (TSS).
DESIGN: Observational.
SETTING: Medizinische Poliklinik, University of Bonn, Germany. PATIENTS: Seven patients with direct or indirect evidence of streptococcal TSS. INTERVENTION: In addition to conventional and supportive therapy, all patients received 2-3 single doses of C1-esterase inhibitor totaling 6,000-10,000 U within the first 24 h after admission. MEASUREMENTS AND
RESULTS: All patients developed fulminant septic shock, multiorgan failure and/or capillary leak syndrome and necrotizing fasciitis within 10-72 h following the onset of first symptoms. Between 1 and 4 days following administration of C1-esterase inhibitor, a marked shift of fluid from extravascular to intravascular compartments took place in all but one patient, accompanied by a transient intra-alveolar lung edema and rapidly decreasing need for adrenergic agents. Six of seven patients survived.
CONCLUSIONS: These clinical observations in a small series of patients and the favorable outcome point towards a positive effect of early and high-dose administration of C1-esterase inhibitor as adjunctive therapy in streptococcal TSS. The possible mechanism involved may be the attenuation of capillary leak syndrome (CLS) via early inactivation of complement and contact systems. Controlled studies are needed to establish an improvement of the survival rates of patients with streptococcal TSS following administration of C1-esterase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126274     DOI: 10.1007/s001340000654

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  6 in total

1.  Validation of C1-esterase inhibitor therapy in severe capillary leak syndrome by monitoring of extravascular lung water.

Authors:  Stefan Kluge; Georg Kreymann
Journal:  Intensive Care Med       Date:  2004-01-16       Impact factor: 17.440

2.  Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors.

Authors:  Mariko Honda-Ogawa; Taiji Ogawa; Yutaka Terao; Tomoko Sumitomo; Masanobu Nakata; Kazunori Ikebe; Yoshinobu Maeda; Shigetada Kawabata
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

3.  Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure.

Authors:  Hoang Pham; Stephanie Santucci; William H Yang
Journal:  Allergy Asthma Clin Immunol       Date:  2014-12-11       Impact factor: 3.406

Review 4.  Complement as driver of systemic inflammation and organ failure in trauma, burn, and sepsis.

Authors:  Marco Mannes; Christoph Q Schmidt; Bo Nilsson; Kristina N Ekdahl; Markus Huber-Lang
Journal:  Semin Immunopathol       Date:  2021-06-30       Impact factor: 9.623

Review 5.  The role of complement system in septic shock.

Authors:  Jean Charchaflieh; Jiandong Wei; Georges Labaze; Yunfang Joan Hou; Benjamin Babarsh; Helen Stutz; Haekyung Lee; Samrat Worah; Ming Zhang
Journal:  Clin Dev Immunol       Date:  2012-09-23

Review 6.  Complement Inhibition and COVID-19: The Story so Far.

Authors:  Sofiane Fodil; Djillali Annane
Journal:  Immunotargets Ther       Date:  2021-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.